New concepts in HIV-1 vaccine development

43Citations
Citations of this article
106Readers
Mendeley users who have this article in their library.

Abstract

With 2 million people newly infected with HIV-1 in 2014, an effective HIV-1 vaccine remains a major public health priority. HIV-1 vaccine efficacy trials in humans, complemented by active and passive immunization studies in non-human primates, have identified several key vaccine-induced immunological responses that may correlate with protection against HIV-1 infection. Potential correlates of protection in these studies include V2-specific, polyfunctional, and broadly neutralizing antibody responses, as well as effector memory T cell responses. Here we review how these correlates of protection are guiding current approaches to HIV-1 vaccine development. These approaches include improvements on the ALVAC-HIV/AIDSVAX B/E vaccine regimen used in the RV144 clinical trial in Thailand, adenovirus serotype 26 vectors with gp140 boosting, intravenous infusions of bNAbs, and replicating viral vectors.

Cite

CITATION STYLE

APA

Stephenson, K. E., D’Couto, H. T., & Barouch, D. H. (2016, August 1). New concepts in HIV-1 vaccine development. Current Opinion in Immunology. Elsevier Ltd. https://doi.org/10.1016/j.coi.2016.05.011

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free